Vimarsana
Biggest News Aggregation in the World

Page 7 - Structural Heart News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Structural Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Structural Heart Today - Breaking & Trending Today

Media Registration for TCT 2024 Now Open - Vimarsana News

Media Registration for TCT 2024 Now Open

Media registration is now open for TCT 2024 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundati

Media Registration for TCT 2024 Now Open - Vimarsana News

Media Registration for TCT 2024 Now Open

Media registration is now open for TCT 2024 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundati

Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer - Vimarsana News

Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer

PRESS RELEASE Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer (CEO). In conjunction with this, and following eight years at the helm of the business, Helmut Straubinger is reti

Source: yahoo.com
Tricares Announces the Appointment of Ahmed Elmouelhi as - Vimarsana News

Tricares Announces the Appointment of Ahmed Elmouelhi as

PRESS RELEASE Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer Paris, France and Munich, Germany, March...

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform - Vimarsana News

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years